Algert Global LLC Sells 154,421 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Algert Global LLC cut its stake in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 62.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 93,062 shares of the company's stock after selling 154,421 shares during the period. Algert Global LLC owned about 0.19% of Cryoport worth $724,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. grew its holdings in Cryoport by 0.4% in the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock valued at $3,012,000 after buying an additional 1,512 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after buying an additional 1,764 shares during the last quarter. Nebula Research & Development LLC boosted its position in shares of Cryoport by 21.6% in the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock valued at $97,000 after acquiring an additional 2,207 shares during the period. Penbrook Management LLC grew its stake in shares of Cryoport by 6.0% in the fourth quarter. Penbrook Management LLC now owns 52,570 shares of the company's stock worth $409,000 after acquiring an additional 2,975 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Cryoport by 8.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company's stock valued at $467,000 after purchasing an additional 4,902 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company's stock.

Insiders Place Their Bets

In other news, CEO Jerrell Shelton sold 4,620 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares in the company, valued at approximately $4,814,359.71. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 19,830 shares of company stock valued at $118,353. 10.00% of the stock is currently owned by corporate insiders.

Cryoport Price Performance

Cryoport stock traded down $0.17 during mid-day trading on Tuesday, hitting $6.98. 289,114 shares of the company were exchanged, compared to its average volume of 542,486. The business has a fifty day moving average of $5.90 and a 200 day moving average of $6.87. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 1-year low of $4.58 and a 1-year high of $14.21. The company has a market capitalization of $349.96 million, a PE ratio of -2.07 and a beta of 1.92.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The company had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. As a group, sell-side analysts expect that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CYRX. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of Cryoport in a report on Thursday, May 8th. Guggenheim reissued a "buy" rating and set a $10.00 target price on shares of Cryoport in a research report on Wednesday, April 16th. UBS Group upped their price target on Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Morgan Stanley decreased their price objective on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. Finally, Roth Mkm restated a "buy" rating and issued a $15.00 target price on shares of Cryoport in a research note on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cryoport presently has an average rating of "Moderate Buy" and an average target price of $11.00.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.